EXAI News and Press, Exscientia Limited From 04/24/24

2024-04-24 09:19:50 ET More on Moderna Moderna Investors Should Beware Patent-Dispute Fallout Moderna: Considering The Cancer Vaccine Angle Moderna Continues To Build A Pipeline S&P 500 stocks with biggest estimated EPS declines for Q1 Moderna sto...

2024-03-27 01:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-21 16:22:02 ET More on Exscientia Exscientia plc (EXAI) Q4 2023 Earnings Call Transcript Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade) Exscientia FY 2023 Earnings Preview Anagenex expands leadership team with a...

2024-03-21 11:53:17 ET More on S&P 500 Index: Chairman Powell Hits A Grand Slam Home Run Despite What The Fed Says, The Policy Is Still 'Higher-For-Longer' The Fed Is More Dovish Than The Market Anticipates 32 “Breakthroughs” stocks by BofA ...

2024-03-21 11:39:10 ET Exscientia plc (EXAI) Q4 2023 Results Conference Call March 21, 2024 8:30 AM ET Company Participants Chinedu Okeke - Associate Director-Strategy, IR Dave Hallett - Interim CEO, Chief Scientific Officer Ben Taylor - CFO, Chief Strategy Offic...

2024-03-21 11:12:18 ET More on Exscientia Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade) Exscientia FY 2023 Earnings Preview Anagenex expands leadership team with appointment of Adrian Schreyer as CTO Seeking Alpha ...

2024-03-21 08:43:23 ET Losers: Destination XL Group DXLG -16% after Q4 earnings release . Tourmaline Bio ( TRML ) -30% . Apyx Medical Corp APYX -17% after Q4 earnings release . Five Below FIVE -12% after Q4 earnings release . Designer Br...

X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...

Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below. Exscientia will host a conference call Thursday, March 21 at 12:30 p.m. GMT / 8:30...

2024-03-20 11:43:37 ET More on Exscientia Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade) Anagenex expands leadership team with appointment of Adrian Schreyer as CTO Exscientia CEO terminated from position due to inappropriate c...